LaBella Nicholas A. Jr. 4

Accession 0001493152-22-035483

CIK 0001859007other

View on SEC.gov Company Profile

Filed

Dec 13, 7:00 PM ET

Accepted

Dec 14, 7:31 PM ET

Size

21.5 KB

Accession

0001493152-22-035483

Insider Transaction Report

Form 4

Period: 2022-12-12

ZyVersa Therapeutics, Inc.ZVSA

LaBella Nicholas A. Jr.

Chief Scientific Officer

Transactions

Award
Stock Options (right to buy)
2022-12-12+39,709→ 39,709 total
Exercise: $5.03Exp: 2025-06-09→ Common Stock (39,709 underlying)
Award
Stock Options (right to buy)
2022-12-12+39,708→ 39,708 total
Exercise: $11.58Exp: 2029-04-02→ Common Stock (39,708 underlying)
Award
Stock Options (right to buy)
2022-12-12+29,781→ 29,781 total
Exercise: $16.36Exp: 2032-01-28→ Common Stock (29,781 underlying)
Award
Common Stock
2022-12-12+18,094→ 18,094 total
Award
Stock Options (right to buy)
2022-12-12+59,563→ 59,563 total
Exercise: $5.03Exp: 2027-10-30→ Common Stock (59,563 underlying)
Award
Stock Options (right to buy)
2022-12-12+29,781→ 29,781 total
Exercise: $16.36Exp: 2031-02-08→ Common Stock (29,781 underlying)
Award
Warrant (right to buy)
2022-12-12+18,094→ 18,094 total
Exercise: $6.90Exp: 2027-12-12→ Common Stock (18,094 underlying)
Award
Stock Options (right to buy)
2022-12-12+19,854→ 19,854 total
Exercise: $5.03Exp: 2024-04-11→ Common Stock (19,854 underlying)

Footnotes (8)

[F1]Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.
[F2]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.
[F3]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016.
[F4]100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
[F5]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
[F6]The option vests in 3 equal annual installments commencing on February 8, 2022.
[F7]The option vests in 3 equal annual installments commencing on January 28, 2023.
[F8]The warrant is immediately exercisable in full.

Documents

1 file

4
ownership.xmlPrimary

Issuer

ZyVersa Therapeutics, Inc.

CIK 0001859007

→

Entity typeother

Related Parties

filerCIK 0001487698

Filing Metadata

Form type: 4
Filed: Dec 13, 7:00 PM ET
Accepted: Dec 14, 7:31 PM ET
Size: 21.5 KB

View on SEC.gov